Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in other brain neurons (72 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10468
Sealed predictions
- NAP1L5 in dopamine neurons, braak+0.59 (p 0.098) → -0.32 (p 0.402)receipt 10475
Swarm cases
receipt 10475: NAP1L5 in dopamine neurons, braak
- power
- full sample +0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.922, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.908, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.16, sign flips 9; without severely affected donors +0.00 (p 0.997, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.67 (p 0.0024, n 18) vs +0.00 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NAP1L5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NAP1L5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 2.1e-4)
Receipts
loading the receipts